AST Test

Your body is constantly repairing and replacing cells. Most of the time, that turnover happens quietly, and you never notice. But when cells in your liver, heart, or muscles are damaged faster than usual, they leak an enzyme called AST (aspartate aminotransferase) into your bloodstream. A simple blood draw can catch that leak, often long before you feel anything wrong.

AST is one of the most widely ordered blood tests in the world, and for good reason. Elevated levels have been linked to shortened life expectancy, increased cancer risk, and cardiovascular disease. Yet many people never look at their AST number unless a doctor flags it, and many doctors use reference ranges that are too generous to catch early trouble.

What AST Actually Tells You

AST lives inside cells throughout your body. The highest concentrations sit in your liver, followed by your heart muscle, skeletal muscles, kidneys, brain, and pancreas. When those cells are injured, whether by inflammation, poor blood flow, toxins, or physical trauma, their membranes break down and AST pours out. The amount in your blood reflects how much cell damage is happening right now.

This is both AST's strength and its limitation. Because it comes from so many tissues, a high reading does not automatically point to your liver. A hard workout, a heart attack, or a muscle injury can all spike your AST. That is why the pattern matters as much as the number itself: AST alongside other liver enzymes like ALT (alanine aminotransferase) narrows the picture considerably.

The AST/ALT Ratio: A Built-In Diagnostic Clue

ALT is much more liver-specific than AST, so comparing the two gives you information neither can provide alone. In most chronic liver conditions, including fatty liver disease and chronic viral hepatitis, ALT runs higher than AST, keeping the ratio below 1.0. When AST overtakes ALT and the ratio climbs above 1.0, it often signals that the liver has progressed to scarring (cirrhosis).

The ratio climbs even higher in alcohol-related liver disease. About 90% of people with alcoholic liver disease have AST levels above their ALT, and more than 70% show a ratio above 2.0. If your AST is elevated but your ALT is normal, the source may not be your liver at all. Isolated AST elevation with a normal ALT should prompt a look at cardiac or skeletal muscle injury.

Liver Disease and Fatty Liver

The most common reason for mildly elevated AST in otherwise healthy adults is metabolic dysfunction-associated steatotic liver disease (MASLD), the medical term for fatty liver driven by metabolic factors. MASLD affects roughly one in three adults. Alcohol-related liver disease is the next most common cause, affecting about one in fifteen people.

Here is the catch that trips up many people: your AST can be completely normal even when your liver is in trouble. Studies consistently show that 11% to 30% of people with biopsy-proven fatty liver inflammation (called NASH, or nonalcoholic steatohepatitis) have normal transaminase levels. The degree of AST elevation does not correlate well with the severity of liver scarring or inflammation. A normal AST does not guarantee a healthy liver, especially if you carry metabolic risk factors like obesity, insulin resistance, or type 2 diabetes.

AST and Mortality Risk

Large population studies have revealed something striking: AST is one of the strongest predictors of how long you are likely to live. The relationship follows a J-shaped curve, meaning both very low and elevated levels carry increased risk, with the lowest mortality sitting in a relatively narrow sweet spot.

Sources: Xie et al. (Taiwanese cohort), Choi et al. (Korean cohort), Ling et al. (NHANES cohort).

What this means for you: an AST that sits persistently above 40 U/L is not a trivial finding. In the Taiwanese cohort, liver-related mortality was about 27 times higher and cancer mortality was roughly 3.6 times higher in people with elevated AST. These associations held even after excluding heavy drinkers, hepatitis carriers, and people who died early in the study.

Cardiovascular Risk

The relationship between AST and heart disease is less straightforward than the mortality data. A study of 16.6 million Korean adults found a positive association between AST levels and both heart attacks and strokes after adjusting for standard cardiovascular risk factors. A study of over 15,000 Hispanic/Latino adults found that elevated AST (above 37 U/L for men, above 31 U/L for women) carried about 1.5 times the risk of cardiovascular events or death.

However, two large meta-analyses pooling data from over a million participants found no statistically significant link between AST alone and cardiovascular mortality. Interestingly, the AST/ALT ratio was a much stronger predictor, with the highest ratios carrying about 2.2 times the risk of cardiovascular death. This suggests that AST's value for heart risk comes from the pattern it forms with ALT rather than from the number by itself.

Cancer Associations

Elevated AST is strongly associated with cancer mortality, particularly cancers of the liver and digestive organs. In the large Taiwanese cohort, people with AST at or above 40 U/L had roughly 3.6 times higher all-cancer mortality. The association was especially pronounced for liver cancer, where elevated AST carried about a 47.6-fold increase in liver cancer mortality. A European case-cohort study following participants for an average of 15.6 years found that people in the highest quartile of AST had about 1.45 times the all-cause mortality risk compared to the lowest quartile.

Reference Ranges

AST reference ranges vary between labs, partly because many labs set their "normal" cutoffs using populations that include people with undiagnosed liver conditions. This means the upper limit printed on your lab report may be higher than the level where real risk begins. Sex affects levels modestly, with men tending to run slightly higher than women.

These tiers draw from ACG guidelines and large population outcome studies. Your lab may use different cutpoints. For the most meaningful interpretation, compare your results within the same lab over time rather than against a single threshold. The AASLD suggests that AST above 30 U/L sustained over six months or longer should prompt evaluation for chronic liver injury, which is below the upper limit many labs print as "normal."

One nuance worth knowing: very low AST (roughly the lowest fifth of the population, around 8 to 18 U/L) has been associated with increased mortality in adults over 70, suggesting the relationship is not simply "lower is always better." This U-shaped pattern means there is a sweet spot rather than a simple target.

When Results Can Be Misleading

AST has a within-person variation (the natural fluctuation in your own levels from one draw to the next, even when nothing has changed) of about 9.5% to 13.9%. That means two blood draws a few weeks apart could give you readings that differ by 10% or more, purely from biological noise. In one large study, 36% of people with an initially elevated AST had a completely normal result when retested.

Intense exercise is one of the most common reasons for a falsely high reading. Because AST lives in skeletal muscle, a hard workout (especially one involving eccentric loading or unfamiliar movements) can push AST well above normal for 24 to 72 hours afterward. If your only elevated liver enzyme is AST and your ALT is normal, muscle damage rather than liver injury is a strong possibility. A creatine kinase (CK) test can help sort this out.

Seasonal patterns can also shift your reading. A time-series analysis of over 1.2 million test results found that AST and ALT levels tend to rise by about 6% during winter months. Laparoscopic surgery can transiently spike AST within 48 hours, typically normalizing by day seven. Fasting status, by contrast, has minimal impact on AST, so you do not need to fast specifically for this test.

AST in Fibrosis Scoring

AST is a key ingredient in several composite scores used to estimate liver scarring without a biopsy. The most widely validated is the FIB-4 index, which combines your age, AST, ALT, and platelet count into a single number. A FIB-4 below 1.3 suggests low risk for advanced scarring; above 2.67 suggests high risk. The American Diabetes Association now recommends FIB-4 screening every one to two years for everyone with type 2 diabetes or prediabetes, since 37% to 70% of people with diabetes have fatty liver disease.

The APRI score (AST-to-platelet ratio index) is another tool that uses AST and platelet count, primarily validated in hepatitis C. These scores are more informative than AST alone, because they capture the interplay between ongoing liver injury and the downstream consequences of scarring.

Tracking Your Trend

A single AST reading is a snapshot, and snapshots can mislead. Given the 10% to 14% natural fluctuation from draw to draw, and the fact that more than a third of initially elevated results normalize on retesting, acting on one number alone is premature. Serial tracking is where the real value lies.

Get a baseline reading. If it is elevated, retest in four to six weeks to confirm (avoiding intense exercise for 48 to 72 hours before the draw). If you are making dietary changes, losing weight, or starting a new supplement or medication, retest in three to six months to see whether your number is moving in the right direction. Once you have a confirmed baseline, retest at least annually.

Because of the natural noise in AST measurements, a change needs to be at least 26% to 38% from your previous reading to confidently represent a true biological shift rather than random variation. Smaller changes could be meaningful if they move consistently in one direction over several readings, which is why tracking the trajectory matters more than obsessing over any single number.